PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of npgopennature.com homepage
Modern Pathology
 
From:
Published online 2016 December 2. doi: 10.1038/modpathol.2016.203

Table 3

Relation between patient characteristics and Ki-67 score
CharacteristicNumber of patients (%)Median Ki-67 score % (interquartile range)P-value
All17940 (24–52) 
    
Age at diagnosis  0.022*
 Median (years)68  
 Interquartile range (years)60–74  
    
Body mass index (kg/m2)  0.663
 <2522 (12)44 (26–58) 
 25–29.935 (20)28 (17–47) 
 ≥3064 (36)41 (26–51) 
 Missing data58 (32)43 (28–55) 
    
Grade   
 139 (22)23 (10–39)<0.0001****
 236 (20)41 (26–50) 
 3104 (58)44 (30–55) 
    
Stage  0.014**
 1108 (60)36 (22–50) 
 222 (12)37 (24–55) 
 342 (24)44 (29–56) 
 46 (3)54 (45–67) 
Missing data1 (1)17 (17–17) 
    
Histological type  0.246
 Endometrioid116 (65)37 (23–51) 
 Non-endometrioida63 (35)44 (28–54) 
    
Lymphovascular space invasion  0.138
 Absent93 (52)37 (22–50) 
 Present70 (39)42 (25–55) 
 Missing data16 (9)45 (31–53) 
    
Depth of myometrial invasion  0.030*
 <50%83 (46)32 (20–50) 
 ≥50%92 (51)43 (28–53) 
 Missing data4 (2)42 (33–51) 
Any adjuvant therapy  0.031*
 No61 (34)32 (22–49) 
 Yesb102 (57)44 (27–55) 
 Missing data16 (9)35 (26–45) 

Ki-67 expression positively correlated with age at the time of surgery, grade, and stage of endometrial cancer. Higher scores were seen in tumors with >50% myoinvasion compared with more superficially invasive cancers and women receiving adjuvant therapy. There was no association between Ki-67 and body mass index, histological type of endometrial cancer, and lymphovascular space invasion (P>0.05).

aGrade 3 endometrioid tumors are classified within the endometrioid subtype. Non-endometrioid tumors include serous, clear cell, carcinosarcomas, mixed, and undifferentiated cancers.
bAdjuvant treatment included external beam radiotherapy (44, 25%), vaginal brachytherapy (21, 12%) or both (25, 14%), and/or chemotherapy (39, 22%), which was single-agent carboplatin (2, 1%) or carboplatin/paclitaxel-based (29, 16%). Data on chemotherapy regime absent in 8 (5%) of cases. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.